Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848128 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
A Phase 3 study, sponsored by Mimetogen Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 642
- Enrollment target
NCT05848128: Completed Phase 3 study, sponsored by Mimetogen Pharmaceuticals USA.
NCT05848128 is a Phase 3 study that has completed, run by Mimetogen Pharmaceuticals USA. The registered enrollment target is 642 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848128, a Phase 3 study, has completed, sponsored by Mimetogen Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 642 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
Primary Outcome
The National Eye Institute (NEI) scale is a standardized grading system of 0-3 was used for each of the 5 areas on each cornea (central, superior, temporal, nasal, and inferior). Grade 0 was specified when no staining is present. The maximum score was 15.
Interventions
- OTHER Vehicle ophthalmic solution
- DRUG 5% Tavilermide ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 642 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2024-05-11 |
| Phase | Phase 3 |
What the finished NCT05848128 record still lists
NCT05848128 is an interventional study that assigns participants to a tested intervention. The registered 642 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle ophthalmic solution is the first listed.
NCT05848128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05848128 about?
NCT05848128 is a clinical study titled "Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye". The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
What is the current status of trial NCT05848128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 642 participants. The study started on 2023-06-28. Estimated completion is 2024-05-11.
What interventions are being tested in trial NCT05848128?
The interventions under investigation include: Vehicle ophthalmic solution (OTHER), 5% Tavilermide ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05848128?
This trial is sponsored by Mimetogen Pharmaceuticals USA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05848128's enrollment target sits among peer trials
642 574th of 2000 higher than 1,426 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT06319820 · 641 participants · Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- NCT06625060 · 641 participants · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI